COYA 301, a recombinant human low-dose interleukin-2 (LD IL-2), and Glucagon-Like Peptide-1 receptor agonists (GLP-1 RAs) have demonstrated potential for synergistic anti-inflammatory effects. This combination targets multiple cell types, including enhancing regulatory T cell (Treg) function, suppressing pro-inflammatory myeloid and T cells, and promoting their conversion to anti-inflammatory phenotypes.
The combination of COYA 301 and GLP-1 RAs has shown promise in addressing various inflammatory diseases, including neurodegenerative conditions such as Alzheimer’s Disease. GLP-1 RAs possess anti-inflammatory and anti-oxidant effects that contribute to their glucose-lowering benefits. Combining them with LD IL-2-mediated Treg enhancement optimizes these effects.
GLP-1 RAs and LD IL-2 have distinct mechanisms of action, exerting anti-inflammatory and Treg-enhancing effects. This multi-targeted approach addresses multiple pathophysiological pathways simultaneously. LD IL-2 enhances Treg function and numbers, suppressing inflammatory responses, while GLP-1 RAs protect neurons, reduce inflammation, and promote neuronal survival.
Coya Therapeutics is investigating these combinations to develop novel therapeutic approaches for severe systemic, neuro-inflammatory, autoimmune, and metabolic conditions. The combination immunotherapy approaches can potentially significantly treat complex immune-based diseases by targeting multiple disease mechanisms.
This proprietary combination expands Coya’s pipeline and can extend the GLP-1 market beyond diabetes and obesity, fostering strategic partnerships and scientific collaborations.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.